An updated expert consensus on nocturnal enuresis (NE) in children, published in the World Journal of Pediatrics, provides a comprehensive framework to improve diagnosis and treatment of a condition that affects self-esteem, sleep, and family life. The new guidance, developed by researchers from the Children's Hospital of Fudan University and the Chinese Cooperative Group for the Management of Pediatric NE, aims to move clinical practice from symptom-based approaches to more standardized, individualized, and family-centered care.
Nocturnal enuresis, commonly known as bed-wetting, affects school-age children and can have significant psychosocial impacts. The condition arises from multiple factors, including excess nighttime urine production, reduced bladder capacity, and difficulty waking to bladder signals. Despite effective treatments, underdiagnosis, inconsistent practice, and poor adherence have limited outcomes. In China, care is further complicated by regional differences in access, cultural perceptions, and uneven coordination between primary and specialist services. Because the previous Chinese consensus was issued in 2014, an updated framework was needed to align with current international standards and expanded domestic clinical experience.
The consensus, published with DOI:10.1007/s12519-026-01051-4, establishes 18 recommendations covering diagnosis, classification, evaluation, first-line therapy, comorbidity management, and referral. One key update lowers the diagnostic threshold: children aged five years or older who experience at least one involuntary nighttime void per month for three months now qualify for diagnosis, a shift from the previous weekly standard that enables earlier intervention. It also mandates a clear distinction between monosymptomatic NE (MNE), where no daytime lower urinary tract symptoms exist, and non-monosymptomatic NE (NMNE), where daytime symptoms such as urgency or incontinence are present. This classification drives treatment decisions.
The voiding diary becomes a diagnostic cornerstone, requiring at least two daytime charts and seven consecutive nights of fluid intake and voids. This allows clinicians to phenotype children as having nocturnal polyuria, reduced bladder capacity, or both. For MNE, treatment is phenotype-driven: desmopressin for nocturnal polyuria and enuresis alarm for reduced bladder capacity, with combination therapy for mixed types. For NMNE, management must prioritize daytime lower urinary tract symptoms and comorbidities, especially constipation, which affects 36% to 80% of these children, before addressing nighttime wetting.
The consensus also outlines clear referral criteria. Primary care may manage MNE, but non-responders or suspected NMNE require specialist evaluation with urodynamics and lumbosacral magnetic resonance imaging. For refractory cases, defined as less than 50% improvement after three months, the framework advises systematic re-evaluation of adherence, diary findings, and underlying causes before escalating treatment. The authors emphasize that NE should not be managed as a single, uniform disorder; instead, clinicians should identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while keeping the family involved.
The practical impact of these recommendations is significant for pediatricians and primary-care clinicians. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment, while earlier attention to constipation, sleep-disordered breathing, ADHD, and daytime urinary symptoms could improve response rates. The framework encourages timely referral when first-line therapy fails or NMNE is suspected, supporting better coordination across levels of care. The authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence remains limited for areas such as desmopressin withdrawal strategies. Future trials and multidisciplinary care models could further refine individualized treatment.
